Impact of mutation status on overall survival (OS), defined from initiation of anti-CTLA-4 treatment (Fig 2a) and from stage IV melanoma (Fig 2b) according to BRAF and NRAS mutation status in all patients (n = 101).
- Joanna Mangana (802398)
- Phil F. Cheng (802399)
- Katja Schindler (802400)
- Benjamin Weide (191119)
- Ulrike Held (20101)
- Anna L. Frauchiger (802401)
- Emanuella Romano (802402)
- Katharina C. Kähler (802403)
- Sima Rozati (389980)
- Markus Rechsteiner (802404)
- Holger Moch (159876)
- Olivier Michielin (25362)
- Claus Garbe (48881)
- Axel Hauschild (103637)
- Christoph Hoeller (268917)
- Reinhard Dummer (103718)
- Simone M. Goldinger (103594)
Publication date
October 2015
DOIAbstract
<p>The Fig 2c represents the OS according to mutation status from diagnosis of metastatic melanoma in the subgroup of patients (n = 76) with no access to BRAF/MEK inhibition treatment.</p
Add to ORKG